Trial Profile
A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Romidepsin (Primary)
- Indications B-cell lymphoma; Hodgkin's disease; Multiple myeloma; T-cell lymphoma
- Focus Adverse reactions
- 23 Oct 2023 Status changed from active, no longer recruiting to completed.
- 03 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 03 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.